Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 2/20 | 0.46 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.46 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.43 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.43 |
| ▸ | MAOA | P21397 | 1/20 | 0.43 |
| ▸ | MAOB | P27338 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | THRB | P10828 | 1/20 | 0.42 |
| ▸ | RECQL | P46063 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29993560 | 1.00 | KCNH2 (0.49) | KCNH2ALDH1A1KMT2ASMN1; SMN2KDM4E | |
| SCHEMBL9941981 | 0.87 | KCNH2 (0.50) | KCNH2ALDH1A1KMT2ASMN1; SMN2KDM4E | |
| SCHEMBL29924651 | 0.83 | ALDH1A1 (0.67) | ALDH1A1KMT2ASMN1; SMN2KDM4EMEN1 | |
| SCHEMBL2491753 | 0.83 | ALDH1A1 (0.67) | ALDH1A1KMT2ASMN1; SMN2KDM4EMEN1 | |
| SCHEMBL5255602 | 0.82 | MAOB (0.52) | KCNH2CYP11B2CYP11B1MAOAMAOB | |
| SCHEMBL3918063 | 0.81 | GSK3B (0.50) | ALDH1A1KMT2ASMN1; SMN2KDM4ETSHR | |
| SCHEMBL30217466 | 0.81 | GSK3B (0.50) | ALDH1A1KMT2ASMN1; SMN2KDM4ETSHR | |
| SCHEMBL196379 | 0.81 | CES2 (0.61) | KCNH2HSP90AB1L3MBTL1ACKR3 | |
| SCHEMBL29746067 | 0.81 | CES2 (0.61) | KCNH2HSP90AB1L3MBTL1ACKR3 | |
| SCHEMBL29712843 | 0.81 | ALDH1A1 (0.69) | ALDH1A1KMT2ASMN1; SMN2KDM4EMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250099431-A1 | GLP-1R MODULATING COMPOUNDS | GILEAD SCIENCES, INC. | 2025-03-27 | — | — | US | disclosed |
| EP-4523751-A2 | GLP-1R MODULATING COMPOUNDS | Gilead Sciences, Inc. (US) | 2025-03-19 | — | — | EP | disclosed |
| EP-4097097-B1 | GLP-1R MODULATING COMPOUNDS | GILEAD SCIENCES INC (US) | 2025-01-15 | — | — | EP | disclosed |
| US-12121511-B2 | GLP-1R modulating compounds | GILEAD SCIENCES, INC. (US) | 2024-10-22 | — | — | US | disclosed |
| EP-4097097-A1 | GLP-1R MODULATING COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2022-12-07 | — | — | EP | disclosed |
| CN-115335374-A | GLP-1R modulating compounds | 吉利德科学公司 | 2022-11-11 | — | — | CN | disclosed |
| US-20220288030-A1 | GLP-1R MODULATING COMPOUNDS | GILEAD SCIENCES, INC. | 2022-09-15 | — | — | US | disclosed |
| WO-2021154796-A1 | GLP-1R MODULATING COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2021-08-05 | — | — | WO | disclosed |
| US-7504391-B2 | Selective D1/D5 receptor antagonists for the treatment of obesity and CNS disorders | SCHERING CORPORATION (US) | 2009-03-17 | — | — | US | disclosed |
| CN-1894213-A | Substituted tetrahydrocarbazole and cyclopentanoindole derivatives | MERCK & CO INC (CA) | 2007-01-10 | — | — | CN | disclosed |
| CN-1751037-A | Sulfonamide derivatives as PPAR modulators | LILLY CO ELI (US) | 2006-03-22 | — | — | CN | disclosed |
| US-6103667-A | Phenylpyrazole herbicides | NOVARTIS CORPORATION (US) | 2000-08-15 | — | — | US | disclosed |
| EP-0832070-A1 | NOVEL HERBICIDES | Novartis AG (CH) | 1998-04-01 | — | — | EP | disclosed |
| WO-1997000246-A1 | NOVEL HERBICIDES | NOVARTIS AG (CH) | 1997-01-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12121511-B2 | GLP-1R modulating compounds | GLP1R, GIPR, GPR119 | KCNH2 3159/4885ALDH1A1 3499/4885KMT2A 3755/4885 |
| US-20250099431-A1 | GLP-1R MODULATING COMPOUNDS | GLP1R, GIPR, GPR119 | KCNH2 3159/4885ALDH1A1 3499/4885KMT2A 3755/4885 |
| US-20220288030-A1 | GLP-1R MODULATING COMPOUNDS | GLP1R, GIPR, GPR119 | KCNH2 3159/4885ALDH1A1 3499/4885KMT2A 3755/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.